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ABSTRACT
Background: Recent studies suggest that blockade of
the NLRP3 (cryopyrin) inflammasome interleukin 1b (IL1b)
pathway may offer a new treatment strategy for gout.
Objective: To explore the potential utility of rilonacept
(IL1 Trap) in patients with chronic active gouty arthritis in
a proof-of-concept study.
Methods: This 14-week, multicentre, non-randomised,
single-blind, monosequence crossover study of 10
patients with chronic active gouty arthritis included a
placebo run-in (2 weeks), active rilonacept treatment
(6 weeks) and a 6-week post-treatment follow-up.
Results: Rilonacept was generally well tolerated. No
deaths and no serious adverse events occurred during the
study. One patient withdrew owing to an injection-site
reaction. Patients’ self-reported median pain visual
analogue scale scores significantly decreased from week
2 (after the placebo run-in) to week 4 (2 weeks of
rilonacept) (5.0 to 2.8; p,0.049), with sustained
improvement at week 8 (1.3; p,0.049); 5 of 10 patients
reported at least a 75% improvement. Median symptom-
adjusted and severity-adjusted joint scores were sig-
nificantly decreased. High-sensitivity C-reactive protein
levels fell significantly.
Conclusions: This proof-of-concept study demonstrated
that rilonacept is generally well tolerated and may offer
therapeutic benefit in reducing pain in patients with
chronic refractory gouty arthritis, supporting the need for
larger, randomised, controlled studies of IL1 antagonism
such as with rilonacept for this clinical indication.
A growing subpopulation of patients with gout can
be characterised as having ‘‘difficult gout’’.
1 These
patients are often intolerant of, or refractory to,
standard therapeutic approaches to gouty inflam-
mation—non-steroidal anti-inflammatory drugs
(NSAIDs), systemic or intra-articular glucocorti-
costeroids, or colchicine.
2 Many patients with
difficult gout have demonstrated intolerance to,
contraindications to, or failure of multiple available
urate-lowering treatments.
1 3–5
Recent data support an important role for
interleukin 1b (IL1b) in the inflammatory process
associated with monosodium urate (MSU) crystal
deposits in tissues of patients with gout. MSU
crystals promote inflammation in large part by
inducing activation of the cryopyrin (NLRP3)
inflammasome, an intracellular, multiprotein com-
plex responsible for cleavage of caspase-1 that is
essential for the processing and secretion of IL1b.
6
The release of IL1b
78promotes neutrophil influx
into the joint that both drives and sustains gouty
inflammation.
1 A recent, open-label, uncontrolled
pilot study of the soluble IL1 receptor antagonist
anakinra suggested benefit in refractory human
gouty inflammation.
9
Rilonacept, a soluble receptor-Fc fusion protein,
engages and inhibits both IL1a and IL1b and has
demonstrated rapid and durable effects in a phase 3
study of patients with cryopyrin-associated peri-
odic syndromes, a spectrum of autoinflammatory
disorders arising from NLRP3 mutations encoding
an aberrant cryopyrin protein and dysregulating
the inflammasome.
10 The proof-of-concept study
reported here explored the potential utility of
rilonacept in patients with chronic, inflamed joints
in whom standard gout treatments were either
contraindicated or failed to alleviate pain and
inflammation.
PATIENTS AND METHODS
Study objectives
The primary objective of this proof-of-concept study
was to assess the safety of rilonacept in patients
with chronic active gouty arthritis. Secondary
objectives were to compare changes in self-reported
pain scores, in patients’ and physicians’ global
assessments and in levels of high-sensitivity
C-reactive protein (hsCRP) during a placebo run-in
phase with those during active treatment. Changes
in inflammatory pathologies of affected joints with
rilonacept treatment were evaluated using a physi-
cian-assessment tool designed specifically for this
study that takes into account both symptoms and
severity in affected joints.
Study design
The study was reviewed and approved by local
institutional review boards, consistent with good
clinical practice and applicable regulatory require-
ments. Written consent was obtained from all
patients. In this 14-week, multicentre, non-rando-
mised, monosequence crossover study, a 1-week
screening period was followed by a single-blind
placebo run-in period of 2-weeks’ duration (week 0
through the end of week 1). Subsequently, patients
entered the active treatment period (week 2
through the end of week 7). A 6-week rilonacept
withdrawal period (week 8 through the end of
week 13) completed the study.
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Major inclusion criteria were diagnosis by a doctor of chronic
active monoarticular or polyarticular gouty arthritis for at least
6 months, with one or more continuously inflamed joints (self-
reported or otherwise) for the 4 or more weeks before screening.
Patients had pain scores of >3 on a 0–10 point visual analogue
scale (VAS). Diagnosis of gout was based on detection of MSU
crystals in the synovial fluid, chronically raised serum urate
levels and/or tophi. Standard treatments for gout, hyperuricae-
mia, flare prophylaxis, or pain had been ineffective or involved
risks related to side effects. Patients were men and women at
least 18 years of age; women of reproductive age agreed to meet
contraception requirements.
Among reasons for exclusion were chronic or active
infection (systemic or joint); estimated glomerular filtration
rate ,30 ml/min; treatment with a live (attenuated) virus
vaccine during the 3 months before study entry; treatment
(,5 half-lives) with an IL1 or a tumour necrosis factor
inhibitor; and a history of listeriosis or tuberculosis.
Treatment
After eligibility determinations, patients were screened within
7 days of the start of the study. Day 0 (baseline) to the end of
week 1 was the single-blind placebo run-in period. The active
treatment period began at week 2 when all patients were
switched to receive single-blind rilonacept, beginning with a
loading dose of 320 mg (two 2 ml injections) administered
subcutaneously, followed by rilonacept 160 mg once a week for
weeks 3 through 7 and ended with the post-treatment with-
drawal phase beginning at week 8. This dosing regimen has been
shown to be well tolerated and efficacious in patients with
cryopyrin-associated periodic syndromes, including improvement
in joint pains, fever and rash,
11 and was felt to offer the possibility
of a favourable risk–benefit assessment. Figure 1 presents the
study design, including dosing and assessment schedule.
Patients were allowed to continue taking their previously
prescribed drugs, including aspirin ((325 mg/day), NSAIDs (to
remain at a stable dose during the trial), allopurinol (if taken for
at least 2 months before baseline), probenecid and colchicine
((1.2 mg daily, if taken at a stable dose for at least 1 month
before baseline).
Safety assessments
Safety was assessed by monitoring treatment-emergent adverse
events (AEs); laboratory values, including anti-rilonacept anti-
bodies; vital signs; chest x-ray findings; electrocardiograms;
physical examinations; and concomitant drugs. AEs and serious
AEs were collected from the time the subject signed the
informed consent form through the final study visit.
Efficacy assessments
Primary efficacy was determined by patient’s pain scores on a
10-point/21-increment VAS which were determined at each
visit for the preceding 24 h. Patients were asked to indicate the
level of pain they had experienced by filling in a circle on the
scale, where ‘‘0’’ was representative of ‘‘no pain,’’ and ‘‘10’’ was
representative of ‘‘severe pain.’’ Additional efficacy end points
included patients’ and physicians’ global assessments; percen-
tage of responders with 50% and 75% improvements in VAS
pain scores; and hsCRP levels. To specifically examine joint
pathologies, the following mean changes were assessed: (a) the
number of all affected joints in which at least one of three
symptoms or signs (swelling, tenderness, or erythema) were
Figure 1 Study design schematic.
Table 1 Patient (n=10) demographics and baseline
characteristics*
Baseline characteristics Value
Age at screening (years)
Mean (SD) 61.5 (10.0)
Median 59.5
Minimum, maximum 50, 78
Sex, n (%)
Male 8 (80)
Female 2 (20)
Race, n (%)
Black or African-American 1 (10)
White 9 (90)
Ethnicity, n (%)
Non-Hispanic/Latino 10 (100)
Comorbidities at baseline, n (%)
Hypertension 10 (100)
Obesity 8 (80)
Hyperlipidaemia 5 (50)
Other cardiac disorders (CHF, CAD) 3 (30)
Upper gastrointestinal disorders 2 (20)
Depression 2 (20)
Anxiety 2 (20)
Moderate renal disease{ 2 (20)
Diabetes 1 (10)
Duration of gout (years)
Mean 13
Minimum, maximum 3, 26
Tophi in >1 joint, n (%) 5 (50)
Weight (kg)
Mean (SD) 105.3 (20.0)
Median 107.6
Minimum, maximum 62.6, 131.5
Height (cm)
Mean (SD) 171.2 (10.6)
Median 170.2
Minimum, maximum 156.3, 187.2
*All patients treated; {glomerular filtration rate (GFR) 30–59 ml/min;
patients with GFR ,30 ml/min were excluded from the study.
CAD, coronary artery disease; CHF, congestive heart failure.
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symptoms/joint (maximum: 3 points/joint); and (c) symptom
severity-adjusted score, weighting by severity of each symptom
(1, mild; 2, moderate; 3, severe) (maximum: 9 points/joint if the
joint was severely swollen, severely tender and severely
erythematous).
Data analysis and statistics
Three comparisons were made for each variable assessed: run-in
phase or placebo effect, by change from baseline to week 2;
active-treatment effect, by change from end of week 2 to end of
week 8; and post-treatment phase or withdrawal effect, by
change from week 8 to week 14. Continuous variables were
analysed using the signed-rank test. Proportions were analysed
by comparing the proportion with 10% using a binomial test.
RESULTS
Of the 15 patients screened, 10 were enrolled and treated. One
patient withdrew owing to an AE. Table 1 lists the demographic
characteristics of the 10 patients treated.
Safety
All patients enrolled received all protocol-specified doses of
rilonacept, except for one patient who discontinued treatment
early. One treated patient, a 50-year-old man, withdrew because
of an adverse event after the second week of rilonacept
injections owing to severe injection site erythema and indura-
tion, both judged to be related to study treatment by the
investigator and both resolved without sequelae.
AEs with rilonacept were rare and most often involved the
injection site. No deaths and no serious AEs occurred during the
study. Vital signs, urine analysis, chemistry, or other laboratory
parameters remained without clinically significant changes.
Three patients in this study tested positive for anti-rilonacept
antibodies at some time point. All antibody titres were low
((1/200) or equal to the minimum required dilution (1/100).
The activity of these antibodies was not rilonacept neutralising.
No correlation was apparent with any specific AE in patients
with anti-rilonacept antibodies and did not appear to affect
efficacy.
Efficacy
During the first 2 weeks of the active treatment phase, median
patients’ self-reported VAS pain scores were significantly
reduced from the placebo run-in phase (5.0 to 2.8; p,0.049)
with sustained improvement after 6 weeks of rilonacept
treatment (week 8) (1.3; p,0.049) (fig 2A). Patients’ (fig 2B)
and physicians’ median global assessment scores showed a trend
towards ‘‘feeling well’’ from the placebo run-in to the end of
active treatment (week 8) and shifted back towards ‘‘feeling
very unwell’’ during the post-treatment follow-up phase.
Figure 2 (A) Patient pain visual analogue score (VAS) (median). *p Value from signed-rank test. Pain scores indicate the level of pain experienced by
the patient over the preceding 24 h and reported at a study visit. On a 10-point scale, ‘‘0’’ represented ‘‘no pain,’’ and ‘‘10’’ represented ‘‘severe pain.’’
(last observation carried forward (LOCF); n=10). The LOCF was used to assign any missing values. (B) Patient’s global assessment score (median). On
a 10-point scale, ‘‘0’’ represented normal/none and ‘‘10’’ represented severe; LOCF; n=10.
{Week 2 vs day 0;
{week 8 vs week 2 (see online
supplementary text files 1 and 2). (C) Symptom and severity-adjusted joint scores (median). Symptom-severity adjusted joint scores were derived by
weighting the joint count by severity (1, mild; 2, moderate; 3, severe) for each symptom (swelling, tenderness and erythema) for each joint for a
possible maximum score of 9 per joint.
{Week 2 vs day 0;
{week 8 vs week 2. (D) High-sensitivity C-reactive protein (hsCRP) levels (median). Normal
limit ,0.287 mg/dl (defined by central laboratory).
{Week 2 vs day 0;
{week 8 vs week 2.
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effect on the number of affected joints (online supplementary
fig 1). However, when the number and severity of symptoms in
all joints were considered, significant differences were seen with
rilonacept treatment. The median symptom-adjusted joint
scores fell from 7.0 at week 2 (end of placebo run-in) to 2.0
with 6 weeks of treatment (week 8) (p,0.049) (online
supplementary fig 2), while the symptom severity-adjusted
median score for all affected joints also fell significantly, from
8.0 at week 2 baseline to 2.5 at week 8 (p,0.049) (fig 2C).
The median symptom-adjusted joint scores and severity-
adjusted joint scores were 2.0 and 2.5 at week 8 (end of
treatment) and 2.0 and 4.0 at week 14 (after withdrawal of
treatment), respectively (online supplementary fig 2 and
fig 2C).
Changes in CRP
Median hsCRP levels were significantly decreased with rilona-
cept treatment from 0.4 mg/dl at week 2 (end of placebo run-in)
to 0.1, 0.1 and 0.2 mg/dl (p=0.002, 0.010 and 0.004) at weeks 4,
6 and 8, respectively (normal level ,0.3 mg/dl) (fig 2D).
Responder analysis
After 6 weeks of rilonacept treatment, 6/of 10 (60%) patients
reported a percentage change in self-reported pain scores that
represented at least a 50% improvement (p,0.001); 5/10 (50%)
of patients had at least a 75% improvement with rilonacept
(p(0.01) (fig 3).
DISCUSSION
This pilot study explored the potential utility of inhibition of
IL1 in patients with chronic active gout, assessing the safety
profile of rilonacept and evaluating changes in disease activity
with its use. The study design, which was monosequence
crossover and non-randomised, including a single-blind placebo
run-in followed by active treatment and subsequent withdrawal
period, allowed for this assessment. In this patient population,
rilonacept was generally well tolerated. Injection site reactions
were the most common AE, usually mild in severity.
Rilonacept administration for 6 weeks also yielded clinical
improvements; specifically, a trend towards progressive
improvement over time. Patients’ self-reported median pain
VAS scores steadily and significantly decreased over the course
of rilonacept treatment. The majority of patients reported at
least a 75% improvement in pain after rilonacept treatment that
was not seen after withdrawal of rilonacept; hsCRP levels
significantly decreased with treatment. This acute phase
reactant change is consistent with evidence correlating circulat-
ing levels of CRP with acute gouty attacks.
12 Although
preliminary, and using a non-validated instrument, symptom-
adjusted and severity-adjusted joint scores showed significant
improvements with rilonacept treatment. These adjusted scores
provided a means to detect significant changes in joint
pathologies with treatment.
Consistent with results in a recent safety and pharmaco-
kinetics trial involving patients with end-stage renal disease,
13
the dosing of rilonacept in this study was not adjusted in the
two patients with moderately impaired kidney function.
The primary limitations of this study were the small cohort
size, a short placebo run-in phase and the absence of
independent blinded joint assessors. This study also did not
directly assess the relative contributions to chronic gouty
arthritis of IL1a and IL1b, both of which are inhibited by
rilonacept. Despite these limitations, this study demonstrated
statistically significant improvement in clinical and laboratory
measures of gout.
In conclusion, this proof-of-concept study provided a positive
signal to suggest that rilonacept may offer a well-tolerated
approach for reducing pain in patients with chronic active
difficult gouty arthritis not adequately managed with other
treatments. The results further support the hypothesis that IL1
blockade may represent a useful and selective treatment
strategy for the growing population of patients with gout,
including chronic, refractory gouty arthritis, suggesting that
rilonacept should be studied further in patients with gout.
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